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Abstract:   
 Sequence variants (SV) are protein products that contain unintended substitutions in the amino 
acid sequence.  SV are one source of heterogeneity inherent to biological systems. They can arise from 
multiple sources within CHO cells including mutations in genomic DNA, transcription and/or translation 
errors, splice variants, and post translational modifications.  This poster focuses on SV resulting from 
single base changes in a copy of the integrated exogenous gene in genomic DNA of single cell cloned 
CHO cell lines.   
 The increased sensitivity and selectivity of analytical instruments and methods has revealed 
across industry that a number of cloned CHO cell lines, including clinical cell lines, contain sequence 
variants.  SV that result in a single amino acid change typically originate in a single base change in the 
coding sequence of the DNA.  At Pfizer, analytical and genetic sequencing methods are now in place to 
screen out clones containing detectable SV.  Extensive clonal sequencing (ECS) of  exogenous gene 
transcripts in over 200 cloned CHO cell lines reveals that the variants are randomly located and are not 
associated with any base change bias or codon position.   
 Digital Droplet PCR (ddPCR) analysis has been utilized to further characterize SV in transcripts 
and trans-gene DNA sequences from four different cloned cell lines to study the impact of cell age as 
well as cell culture process conditions on the level of SV in both mRNA and genomic DNA.  SV levels in in 
the protein product were also characterized using LC/MS to link SV levels in DNA, mRNA and protein.  
Data so far suggest SV-containing cloned cell lines fall into two distinct categories; variants that are 
present in only a sub-population of cells and variants present in the whole population of cells.   Results 
of this study with hypotheses to support population dynamic models will be presented. 
